A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this ...
The aberrant overexpression of Lysine-specific demethylase 1 (LSD1/KDM1A) is a common feature across a wide spectrum of human cancers, and its elevated levels correlate with poor survival of cancer ...
When proteins cause disease, the body has ways to tackle them. An emerging class of therapies that leverage a cell’s built-in systems to eliminate rogue proteins has already reached the clinic via ...
A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to cancer cells and not normal cells, potentially allowing clinicians to ...
Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants. In one current study, they have focused on the disease ...
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability The US Food and Drug ...
A new active substance attacks a key protein in tumour cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback